Cancer drug combo trial halted before it began
NCT ID NCT07146919
First seen Apr 24, 2026 · Last updated Jun 14, 2026 · Updated 7 times
Summary
This study aimed to test the safety and effectiveness of combining two drugs, bemarituzumab and bevacizumab, in people with advanced or metastatic endometrial, ovarian, or cervical cancers that have a specific protein called FGFR2b. The trial was withdrawn before enrolling any participants, so no results are available. The goal was to find the best dose and see if the combination could slow or stop cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.